Log in

Relevant bibliographies by topics / Drug problems

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Drug problems'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug problems.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug problems"

1

Plant, Martin A. "Drugs and drug problems." Midwifery 1, no. 3 (September 1985): 133–34. http://dx.doi.org/10.1016/s0266-6138(85)80030-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Burger, Candice. "Treat Drug Problems With Drugs?" Contemporary Psychology: A Journal of Reviews 30, no. 7 (July 1985): 556. http://dx.doi.org/10.1037/023917.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Randall, Helen. "Drug promotional problems." Medical Journal of Australia 150, no. 8 (April 1989): 463. http://dx.doi.org/10.5694/j.1326-5377.1989.tb136573.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gerstein, Dean R., and Lawrence S. Lewin. "Treating Drug Problems." New England Journal of Medicine 323, no. 12 (September 20, 1990): 844–48. http://dx.doi.org/10.1056/nejm199009203231230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Fai-kam, Kanyanat, Yatima Nuchdang, Yupawarat Kentekrom, Prayuth Chusorn, and Pornpimon Chusorn. "Preventing and solving the narcotic drug problems in Thailand." New Trends and Issues Proceedings on Humanities and Social Sciences 2, no. 2 (January 12, 2016): 37–41. http://dx.doi.org/10.18844/gjhss.v2i2.413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gonçalves, Angelica, Ana Arciprete, Tereza Barroso, and Sandra Pillon. "Cross-cultural adaptation and validation of the Drug and Drug Problems Perceptions Questionnaire for Brazil." Revista de Enfermagem Referência IV Série, no. 19 (December 26, 2018): 11–20. http://dx.doi.org/10.12707/riv18014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Pennings, Pleuni S. "HIV drug resistance: problems and perspectives." Infectious Disease Reports 5, no. 1S (June 6, 2013): 5. http://dx.doi.org/10.4081/idr.2013.s1.e5.

Full text

Abstract:

Access to combination antiretroviral treatment (ART) has improved greatly over recent years. At the end of 2011, more than eight million HIV-infected people were receiving ART in low-income and middle-income countries. ART generally works well in keeping the virus suppressed and the patient healthy. However, treatment only works as long as the virus is not resistant against the drugs used. In the last decades, HIV treatments have become better and better at slowing down the evolution of drug resistance, so that some patients are treated for many years without having any resistance problems. However, for some patients, especially in low-income countries, drug resistance is still a serious threat to their health. This essay will review what is known about transmitted and acquired drug resistance, multi-class drug resistance, resistance to newer drugs, resistance due to treatment for the prevention of mother-to-child transmission, the role of minority variants (low-frequency drug-resistance mutations), and resistance due to pre-exposure prophylaxis.

APA, Harvard, Vancouver, ISO, and other styles

8

Garcia, Maria Lúcia Teixeira. "Russia and Intolerance towards Drug Problems." Journal of Sociological Research 5, no. 1 (May 19, 2014): 113. http://dx.doi.org/10.5296/jsr.v5i1.5648.

Full text

Abstract:

The aim of this article is to examine the problem of drug use in Russia by analysing the direction taken by the drug policies in that country. We conducted an Internet-based literature search using two keywords in English: Russia and drug policy. We began reading the materials identified in the search and organising data. The other sources we used included the websites for the World Health Organization and the Federal Drug Control Service of the Russian Federation. The estimated number of people who use illegal drugs in Russia is five million, and of these, 1.7 million are opiate users. In 2012, approximately 2.5 million Russians were drug-dependent[1], and 90% of them used heroin from Afghanistan. With a population of 143 million people, Russia consumes 70 tons of Afghan heroin every year – more than one-fifth of the drug consumed globally – according to the United Nations Office on Drugs and Crime. Russian drug policy thus calls the world’s attention to what we should not do: focus public policy on actions known to be ineffective for responding to drug use problems.[1] CNPq and Fapes researcher. Research study (no. 485937/2012-3) funded by CNPq – Brazilian National Council for Scientific and Technological Development. Member of Fênix group2 The number of heroin users in countries in Western Europe such as Germany or the United Kingdom is significantly lower – up to 150,000 and 300,000, respectively, according to several estimates.

APA, Harvard, Vancouver, ISO, and other styles

9

Bor, Andrea, Mária Matuz, Péter Doró, Réka Viola, and Gyöngyvér Soós. "Drug-related problems in the elderly." Orvosi Hetilap 153, no. 49 (December 2012): 1926–36. http://dx.doi.org/10.1556/oh.2012.29500.

Full text

Abstract:

The aging population in developed countries is a growing problem nowadays. The burden on healthcare is particularly high, since the prevalence of the diseases, especially chronic diseases increases with age. Prevalence of polypharmacy is common among elderly patients. While comorbidities require usage of several active agents with evidence based indication, polypharmacy increases the likelihood of interactions and adverse drug reactions, reduces patient compliance, affects quality of life and puts a significant financial burden on the patient and society. In order to reduce drug-related problems among the elderly, different lists of potentially inappropriate drugs and doses were created. One of the earliest known lists is the “Beers criteria”. The use of listed drugs is risky and not recommended for elderly patients. Following foreign examples, a list was compiled and adapted to the Hungarian drug spectrum based on the main concerns and alternative therapeutic suggestions. Orv. Hetil., 2012, 153, 1926–1936.

APA, Harvard, Vancouver, ISO, and other styles

10

Hanlon, Joseph T. "Drug-related problems updates." American Journal of Geriatric Pharmacotherapy 2, no. 1 (March 2004): 88–90. http://dx.doi.org/10.1016/s1543-5946(04)90011-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Drug problems"

1

Mannheimer, Buster. "Drug-related problems with special emphasis on drug-drug interactions." Stockholm : Department of Clinical Science and Education, Karolinska Institutet, 2009. http://diss.kib.ki.se/2009/978-91-7409-602-6/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Barry, Peter Walter. "Problems with inhalational drug delivery." Thesis, University of Leicester, 1999. http://hdl.handle.net/2381/29591.

Full text

Abstract:

Inhalational therapy is used to deliver medication to the lung, either to treat diseases or, less commonly, for systemic absorption. A number of devices have been developed to aid or improve inhalational therapy, and this thesis deals with metered dose inhalers, used with spacer devices, and nebulisers. Despite their seemingly simple construction and concept, the correct choice and use of an inhalational drug delivery device can dramatically alter the amount of drug available for inhalation. Studies in this thesis, supported by emerging pharmacokinetic evidence, have highlighted areas where the device can affect the drug delivery. In vitro methods were used to quantify and characterise the different devices, including inertial impaction for aerosol particle sizing, sinus flow pumps for breathing simulation and high speed video recordings to analyse aerosol plume geometry and spacer function. The results these studies reveal a number of factors that may affect drug delivery. Firstly, delay between metered dose inhaler actuation into a spacer and inhalation can reduce the amount of drug available to the patient. Secondly, multiple actuations of the metered dose inhaler into the spacer prior to inhalation also reduce the amount of drug available. The size of the spacer may also affect the amount of drug available for inhalation, and this will vary with the drug prescribed. Different formulations may differ in their aerosol cloud speed and volume, and this may alter the amount of drug delivered from different spacers. Plastic and polycarbonate spacers may be highly charged with static electricity. Such spacers deliver less drug than those where the static charge has been reduced by an anti-static lining, or where the spacer is constructed from static dissipative materials. Washing the spacer also reduces its charge, but the optimum washing regime for spacers is not known. Different nebulisers deliver different amounts of drug, and the assessment of nebulisers varies with the method used. Accurate assessment should include direct measurement of the mass of drug released, and should incorporate simulated patient breathing. Effective nebulisation of drug ends after a few minutes. This time will depend on the nebuliser and drug being used, but for some medications administered for asthma, little drug may be delivered after five minutes, and patients should be advised to stop nebulisation after this time. In conclusion, studies in this thesis support the hypothesis that the method of use or choice of inhalational drug delivery device affects the amount of drug that is available for inhalation by the patient.

APA, Harvard, Vancouver, ISO, and other styles

3

Al-Deagi, Fawzi A. A. "Drug-related problems in elderly patients." Thesis, Queen's University Belfast, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318951.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Easton-Carter, Kylie 1973. "The consequences of drug related problems in paediatrics." Monash University, Dept. of Pharmacy Practice, 2001. http://arrow.monash.edu.au/hdl/1959.1/8988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ibrahim, N. "Drug-related problems (DRPs) in children with kidney disease." Thesis, University College London (University of London), 2014. http://discovery.ucl.ac.uk/1448344/.

Full text

Abstract:

Introduction: Medicines are used with the intention of benefitting from their effect. The effects of medicines can also be undesirable and potentially lead to harm. A drug-related problem (DRP) is a term used to describe problem(s) that exist in the use of medicines. There remains a distinct paucity of data on the epidemiology of DRPs in children with kidney disease. Aim: To investigate the epidemiology of DRPs in children with kidney disease in clinical practice at tertiary Paediatric Nephrology units. Methods: Study 1: Prospective observational study on the characteristics of DRPs in hospitalised children with kidney disease. Study 2: Randomised control trial on clinical pharmacist (CP) interventions in resolving DRPs on the renal outpatient clinic. Results: Study 1: A total of 127 patients were recruited and a total of 203 DRPs were identified. The incidence of DRP was 51.2% (95% CI 43.2-60.6%) of patients reviewed by the CPs. The number of medicines prescribed per child was the only significant risk factor for the occurrence of DRPs (OR 1.06, 95% CI 1.02-1.10, p=0.002). The majority of DRPs were minor in clinical significance (68%, n=138/203). The predominant DRPs were sub-optimal drug effect. These DRPs were associated with drug selections and dosage errors. Study 2: A total of 100 patients were recruited (Control n=53, Intervention n=47). The trial showed no effect of intervention in the resolution of active DRPs (p=0.96) between the Control and Intervention arms. Conclusion: DRPs are common in children with kidney disease and necessitate a comprehensive approach to their identification and resolution. Their characteristics in both settings are different even though the majority of them shared a similar level of clinical significance. Further research is required to evaluate the effectiveness of pharmacists’ intervention in resolving DRPs at the outpatient clinics.

APA, Harvard, Vancouver, ISO, and other styles

6

Gordon, Karen Joyale. "Drug related problems in cardiovascular patients in primary care." Thesis, University College London (University of London), 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269639.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Morrison, Valerie L. "Illicit drug use : patterns, problems, and predictors of change." Thesis, University of Edinburgh, 1993. http://hdl.handle.net/1842/20033.

Full text

Abstract:

This thesis describes the results of a longitudinal study of regular illicit drug users in Edinburgh, Scotland. Subjects were recruited using the method of 'snowballing'. An initial group of 115 regular users of illicit substances was interviewed using a semi-structured schedule. It was found that multiple substance use was the norm with many individuals reporting adverse consequences resulting from their use of licit and illicit drugs. Concern about HIV infection affected the drug taking behaviour of injectors, but in contrast, had little influence upon the sexual behaviour of both injectors and non-injectors. Sixty-three percent (n = 72) of respondents were reinterviewed approximately 18 months after the initial interview, in order to assess patterns of behaviour change. It was hypothesised that level of involvement in drug-using lifestyles at first interview and repondents' cognitions about their current and future use would be predictive of behaviour change at the time of follow-up. Drug involvement variables, such as length of drug using career, opiate use and having an income from drug dealing, discriminated significantly between users who 'reduced' in terms of the nature and level of their use, and those who 'progressed' or remained 'static'. Cognitions about use, such as perceptions of being addicted and desire to stop, discriminated 'statics' from the 'reducers' and 'progressors'. Results from this study show that drug use behaviour change has multiple predictors at personal, social and environmental levels. These predictors are as varied and complex as those of drug initiation suggested in the retrospective data. Further studies of predictors of change should facilitate the identification of those new users who are 'at risk' of progression, which would have important implications for both primary and secondary prevention.

APA, Harvard, Vancouver, ISO, and other styles

8

Boys, Annabel Frances. "Young substance users : modelling consumption patterns, problems and expectations." Thesis, King's College London (University of London), 2001. https://kclpure.kcl.ac.uk/portal/en/theses/young-substance-users--modelling-consumption-patterns-problems-and-expectations(350a7ff3-f70f-4d4a-9acb-814c5ded88d5).html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Campbell, Michael, Mobeen Moslem, Preston Spriggel, and Terri Warholak. "Identifying Drug Therapy Problems Through Patient Consultation at Community Pharmacies." The University of Arizona, 2013. http://hdl.handle.net/10150/614231.

Full text

Abstract:

Class of 2013 Abstract
Specific Aims: The objective of this quality improvement project is to evaluate if drug therapy problems in a community pharmacy setting can be identified via patient counseling at the time of prescription pick up. The central hypothesis of the project is that patient consultation will aid in identifying drug therapy problems and reduce the amount of negative effects posed by these problems. Methods: This project will assess data obtained through a medication therapy intervention report utilized in multiple community pharmacy environments in Arizona. Any consultation provided to a patient by a pharmacist or pharmacy intern regarding a new or transferred prescription will be eligible for data collection. The primary dependent variable is the number of drug therapy problems identified during consultation. Drug therapy problems will be assessed via expert opinion to identify the potential negative impact they may have posed to patients. Data analysis will involve the frequency and type of drug therapy problems identified during data collection. Main Results: A total of 1305 prescriptions were screened during the data collection period. A total of 29 drug therapy problems were identified upon patient consultation. This yielded a 2.2% drug therapy problem occurrence during data collection. The most commonly occurring drug therapy problem involved a patient drug allergy or sensitivity issue. Conclusion: Future research is warranted on the effects that drug therapy problems have on patients and the healthcare system. This project is descriptive in nature and may not be applicable to every community pharmacy in Arizona.

APA, Harvard, Vancouver, ISO, and other styles

10

Akhter, K. P. "Computational problems associated with fitting the Michaelis-Menten models." Thesis, University of Manchester, 1988. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.233023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Drug problems"

1

Study, Institute of Medicine Committee for the Substance Abuse Coverage. Treating drug problems. Washington, D.C: National Academy Press, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Treating drug problems. Hoboken, N.J: John Wiley & Sons, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

name, No. Problems in pediatric drug therapy. 4th ed. Washington, DC: American Pharmaceutical Association, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

1959-, Scratchley David, and Royce James E, eds. Alcoholism and other drug problems. New York: Free Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Royce, James E. Alcoholism and other drug problems. New York: Free Press, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mazerolle, Lorraine Green. Policing places with drug problems. Thousand Oaks: Sage Publications, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Drug abuse and drug-related crimes: Some unresolved legal problems. Dordrecht: M. Nijhoff Publishers, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Locke, Trevor. Organised responses to urban drug problems. Leicester: Leicester Polytechnic, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Webber, Anne. Drug problems: Where to get help. 2nd ed. London: BBC Books, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Upadhyay, Bharatji. The drug addicts: Problems and solutions. Varanasi: Vijay Prakashan Mandir, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Drug problems"

1

Whynes, David. "Drug Problems, Drug Policies." In Policing and Prescribing, 1–14. London: Palgrave Macmillan UK, 1991. http://dx.doi.org/10.1007/978-1-349-11451-1_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kerfoot, Michael, and Alan Butler. "Drug Abuse." In Problems of Childhood and Adolescence, 101–16. London: Palgrave Macmillan UK, 1988. http://dx.doi.org/10.1007/978-1-349-19311-0_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Goode, Erich. "Drug Use." In Social Problems and Mental Health, 59–65. London: Routledge, 2022. http://dx.doi.org/10.4324/9781003261919-17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sobell, Mark B., D. Adrian Wilkinson, and Linda C. Sobell. "Alcohol and Drug Problems." In International Handbook of Behavior Modification and Therapy, 415–35. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0523-1_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Gear, Sarah. "Drug and alcohol problems." In The Complete MRCGP Study Guide, 205–8. 4th ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781846198397-25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lapham, Robert. "Answers to Problems." In Drug Calculations for Nurses, 314–81. 5th ed. London: Routledge, 2021. http://dx.doi.org/10.4324/9781003057062-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Thompson, Neil. "Problematic Drug Use." In Social Problems and Social Justice, 150–64. London: Macmillan Education UK, 2017. http://dx.doi.org/10.1057/978-1-137-60362-3_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Biglan, Anthony, Brian Flay, and Sharon L. Foster. "The Prevention of Drug Abuse." In Preventing Youth Problems, 87–111. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4757-6236-5_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Moorcraft, Sing Yu. "Cancer drug development and funding." In Clinical Problems in Oncology, 277–86. Hoboken, NJ: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118673768.ch10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Leukefeld, Carl G., Thomas W. Miller, and Lon Hays. "Drug abuse." In Finding solutions to social problems: Behavioral strategies for change., 373–96. Washington: American Psychological Association, 1996. http://dx.doi.org/10.1037/10217-014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug problems"

1

Dörsam, S., E. Friedmann, and J. Stein. "MODELING AND SIMULATIONS OF DRUG DISTRIBUTION IN THE HUMAN VITREOUS." In Topical Problems of Fluid Mechanics 2017. Institute of Thermomechanics, AS CR, v.v.i., 2017. http://dx.doi.org/10.14311/tpfm.2017.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

BROGLIA, R. A., and G. TIANA. "FROM ATOMIC NUCLEI TO DRUG DESIGN." In Proceedings of the 9th Conference on Problems in Theoretical Nuclear Physics. WORLD SCIENTIFIC, 2003. http://dx.doi.org/10.1142/9789812705143_0035.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Jablonowski, Lauren J., and Margaret A. Wheatley. "Circumventing drug delivery problems in advanced pancreatic cancer treatment." In 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC). IEEE, 2015. http://dx.doi.org/10.1109/nebec.2015.7117049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Câmpean, Remus. "Robust Simulation for Decisional Problems Applied for Drug Testing." In Tenth International Conference on Computer Modeling and Simulation (uksim 2008). IEEE, 2008. http://dx.doi.org/10.1109/uksim.2008.51.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Filchenko, Andrey Petrovich, Vladimir Yurievich Zhandrov, and James E. Gonzales. "Countering Drug Sale Street Advertising." In VII INTERNATIONAL SCIENTIFIC-PRACTICAL CONFERENCE “CRIMINAL LAW AND OPERATIVE SEARCH ACTIVITIES: PROBLEMS OF LEGISLATION, SCIENCE AND PRACTICE”. SCITEPRESS - Science and Technology Publications, 2021. http://dx.doi.org/10.5220/0010636000003152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

JANCA, ALEKSANDAR, OYE GUREJE, and LINDA A. BENNETT. "ASSESSMENT OF ALCOHOL- AND DRUG-RELATED PROBLEMS IN DIFFERENT CULTURES." In IX World Congress of Psychiatry. WORLD SCIENTIFIC, 1994. http://dx.doi.org/10.1142/9789814440912_0121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lee, Vivian WY. "26 Managing drug-related problems in advanced heart failure patients." In 1st Asia Pacific Advanced Heart Failure Forum (APAHFF), 15th December 2017, Hong Kong. BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association, 2018. http://dx.doi.org/10.1136/heartasia-2018-apahff.26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Vázquez-Real, M., Á. Alcalá-Soto, DS Ruiz-Pérez, MDV Sanchez Matamoros Piazza, and JF Sierra-Sánchez. "6ER-024 Potentially drug-related problems in a polymedicated population." In 26th EAHP Congress, Hospital pharmacists – changing roles in a changing world, 23–25 March 2022. British Medical Journal Publishing Group, 2022. http://dx.doi.org/10.1136/ejhpharm-2022-eahp.369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Vasilyeva, Klavdiya Kirillovna, Darya Nikolaevna Krotova, and Osor Rygzynovich Ochirov. "Social Prevention of Drug Trafficking Crimes." In VII INTERNATIONAL SCIENTIFIC-PRACTICAL CONFERENCE “CRIMINAL LAW AND OPERATIVE SEARCH ACTIVITIES: PROBLEMS OF LEGISLATION, SCIENCE AND PRACTICE”. SCITEPRESS - Science and Technology Publications, 2021. http://dx.doi.org/10.5220/0010627500003152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Shum, Ho Cheung, Tiantian Kong, Zhou Liu, and Yang Song. "Engineering Drug Delivery Vehicles With Multiphase Microfluidics." In ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93028.

Full text

Abstract:

In our work, we propose the use of multiphase microfluidics to prepare drug delivery vehicles with complex structures, such as core-shell capsules, multicompartment microspheres and nonspherical particles; by tailoring the spatial distribution of drugs, unconventional drug release profiles can be achieved. To avoid the use of harmful organic solvents, we introduce the use of aqueous two-phase systems in microfluidics to generate the emulsion templates for making these novel delivery vehicles. By manipulating the interfacial characteristics of the emulsion templates, complex structures with hydrophilic and hydrophobic compartments can be prepared for separate encapsulation and sequential release of both hydrophilic and hydrophobic drugs. We will discuss the fundamental problems that need to be addressed to generate these drug delivery vehicles and highlight their potential by demonstrating their release characteristics.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drug problems"

1

Ruhm, Christopher. Deaths of Despair or Drug Problems? Cambridge, MA: National Bureau of Economic Research, January 2018. http://dx.doi.org/10.3386/w24188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Cohen, Lauren, Umit Gurun, and Danielle Li. Internal Deadlines, Drug Approvals, and Safety Problems. Cambridge, MA: National Bureau of Economic Research, November 2020. http://dx.doi.org/10.3386/w28071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ni, Xiaofeng, Chunsong Yang, Yumei Bai, Zixian Hu, and Lingli Zhang. Drug-Related Problems of Patients in Primary Heath Care Institutions: a Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chatterji, Pinka, and Sara Markowitz. The Impact of Maternal Alcohol and Illicit Drug Use on Children's Behavior Problems: Evidence from the Children of the National Longitudinal Survey... Cambridge, MA: National Bureau of Economic Research, May 2000. http://dx.doi.org/10.3386/w7692.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Norsworthy, Sarah, Rebecca Shute, Crystal M. Daye, and Paige Presler-Jur. National Institute of Justice’s Forensic Technology Center of Excellence 2019 National Opioid and Emerging Drug Threats Policy and Practice Forum. Edited by Jeri D. Ropero-Miller and Hope Smiley-McDonald. RTI Press, July 2020. http://dx.doi.org/10.3768/rtipress.2020.cp.0011.2007.

Full text

Abstract:

The National Institute of Justice (NIJ) and its Forensic Technology Center of Excellence (FTCoE) hosted the National Opioid and Emerging Drug Threats Policy and Practice Forum on July 18–19, 2019, in Washington, DC. The forum explored ways in which government agencies and programs, law enforcement officials, forensic laboratory personnel, medical examiners and coroners, researchers, and other experts can cooperate to respond to problems associated with drug abuse and misuse. Panelists from these stakeholder groups discussed ways to address concerns such as rapidly expanding crime laboratory caseloads; workforce shortages and resiliency programs; analytical challenges associated with fentanyl analogs and drug mixtures; laboratory quality control; surveillance systems to inform response; and policy related to stakeholder, research, and resource constraints. The NIJ Policy and Practice Forum built off the momentum of previous stakeholder meetings convened by NIJ and other agencies to discuss the consequences of this national epidemic, including the impact it has had on public safety, public health, and the criminal justice response. The forum discussed topics at a policy level and addressed best practices used across the forensic community.

APA, Harvard, Vancouver, ISO, and other styles

6

Garber, Judith, and Shannon Brownlee. Medication Overload: America's Other Drug Problem. Lown Institute, April 2019. http://dx.doi.org/10.46241/li.wouk3548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wynne, Charles E. Colombia: More Than Just a Drug Problem. Fort Belvoir, VA: Defense Technical Information Center, January 2003. http://dx.doi.org/10.21236/ada442515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Cheng, and Yue Yang. Impact of adaptive design on reducing the duration of clinical trials in rare cancers: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0081.

Full text

Abstract:

Review question / Objective: Whether the application of adaptive design in clinical trials of rare cancers can shorten the duration of clinical trials? Condition being studied: Currently, the development of innovative drug products (InMPs) for rare cancers faces many challenges, including the difficulty of enrolling sufficient numbers of patients from small and heterogeneous patient populations for clinical trials, and the significant risks of high financial investment, long development times and potential failure from a pharmaceutical company's perspective for rare cancer drugs due to limited knowledge of the natural history of the disease. Therefore, alternative approaches to clinical trial design are needed to conduct cost-effective, well-controlled analyses that can assess treatment effects in small, heterogeneous populations within shorter time frames. Adaptive trials, on the other hand, may be an effective solution to this problem. Adaptive clinical trials are designed to accelerate the clinical trial process by making predefined adjustments to key parameters through data accumulated at predefined time points during the trial without compromising the integrity and validity of the results.This study aims to examine the value of adaptive design in reducing the duration of clinical trials in rare cancers and encourage their wider implementation.

APA, Harvard, Vancouver, ISO, and other styles

9

Horwitz, Jill, Corey Davis, Lynn McClelland, Rebecca Fordon, and Ellen Meara. The Problem of Data Quality in Analyses of Opioid Regulation: The Case of Prescription Drug Monitoring Programs. Cambridge, MA: National Bureau of Economic Research, August 2018. http://dx.doi.org/10.3386/w24947.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Patron, Maria Carmela, and Marilou P. Costello. The DMPA service provider: Profile, problems and prospects, August 1995. Population Council, 1995. http://dx.doi.org/10.31899/rh1995.1024.

Full text

Abstract:

This report presents the results of interviews conducted with 60 trained DMPA service providers from seven of the ten local government units (LGUs) covered by Phase I of the Philippine Department of Health's DMPA Reintroduction Program. DMPA, or Depot-medroxyprogesterone acetate, is an injectable contraceptive commonly known as Depo-Provera. The interviews were undertaken as part of the DMPA Monitoring and Follow-up Studies sponsored by the Population Council under the Asia and Near East Operations Research and Technical Assistance (ANE OR/TA) Project. While the monitoring study and the follow-up survey focused on DMPA users and dropouts, this study centered on the service provider. The DMPA Reintroduction Program was launched by the DOH in April 1994 by the Philippine Bureau of Food and Drugs. The program aims to reintroduce DMPA into the Philippine Family Planning Program through training local-level doctors, nurses, and midwives as service providers, and providing free DMPA services in selected public health facilities.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!